IQVIA Holdings Inc. $IQV Shares Purchased by Korea Investment CORP

Korea Investment CORP raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 32.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 172,009 shares of the medical research company’s stock after acquiring an additional 42,281 shares during the period. Korea Investment CORP owned 0.10% of IQVIA worth $27,107,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund purchased a new position in IQVIA during the second quarter worth about $819,000. Elevation Point Wealth Partners LLC acquired a new position in shares of IQVIA during the 2nd quarter valued at about $64,000. Quadrant Capital Group LLC lifted its holdings in shares of IQVIA by 82.2% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,651 shares of the medical research company’s stock worth $733,000 after acquiring an additional 2,099 shares during the period. Vinva Investment Management Ltd boosted its position in shares of IQVIA by 90.7% in the second quarter. Vinva Investment Management Ltd now owns 161,383 shares of the medical research company’s stock worth $25,674,000 after acquiring an additional 76,778 shares during the last quarter. Finally, Employees Retirement System of Texas purchased a new stake in IQVIA in the second quarter valued at approximately $231,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 1.8%

Shares of NYSE:IQV opened at $227.63 on Friday. The company has a market capitalization of $38.77 billion, a price-to-earnings ratio of 31.23, a price-to-earnings-growth ratio of 2.60 and a beta of 1.34. The company has a 50 day moving average of $210.07 and a two-hundred day moving average of $183.55. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $234.29. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Truist Financial reiterated a “buy” rating and issued a $265.00 price target (up previously from $235.00) on shares of IQVIA in a report on Wednesday, October 29th. UBS Group lifted their target price on IQVIA from $225.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. JPMorgan Chase & Co. upped their price target on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. BMO Capital Markets started coverage on IQVIA in a report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price objective on the stock. Finally, Baird R W upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $240.61.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.